News

Yahoo Finance1y
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
OCALA, Fla., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the last subject has completed treatment in the Company’s ...
Yahoo Finance4y
AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen
AIM is funding the clinical study. The company is working to finalize the study protocol and will announce new information as it becomes available. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is ...
Business Insider1y
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment ...
AIM announced in January 2023 that it had entered into an external sponsored collaborative clinical research agreement with Erasmus MC and AstraZeneca. The DURIPANC Study is an investigator ...
Nasdaq2y
AIM ImmunoTech Commences Phase 2 Study Of Ampligen For Pancreatic Cancer Treatment
(RTTNews) - AIM ImmunoTech Inc. (AIM) said that it has commenced its Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer (AMP-270) following receipt of Institutional ...
Business Insider1y
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
AIM Chief Executive Officer Thomas K. Equels commented, “With dosing now complete, our AMP-518 focus turns to the next milestone of being able to report topline study data as soon as it is ...